Home >> Tag Archives: Biocare Medical—

Tag Archives: Biocare Medical—

IHC antibody, 11/15

November 2015—Biocare Medical announced the availability of CK HMW + p63 + AMACR (RM) as an in vitro diagnostic double stain for multiplex immunohistochemistry. This patented antibody cocktail may be useful in the evaluation of normal prostate glands, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.

Read More »

Monoclonal antibody patent issued

January 2015—Biocare Medical has been awarded a U.S. patent for its anti-PAX8 mouse monoclonal antibody, clone [BC12]. The PAX8 antibody [BC12] is designed to target a restricted epitope and exhibits higher specificity and provides sharper staining than the PAX8 rabbit polyclonal antibody.

Read More »

Automated slide staining system, 7/14

July 2014—Biocare Medical expanded its automated instrumentation offering with the Oncore Automated Slide Staining System. The Oncore is a compact benchtop instrument that performs both immunohistochemistry and in situ hybridization tests on formalin-fixed, paraffin-embedded tissues.

Read More »

ASI, Biocare partnership, 2/14

February 2014—Applied Spectral Imaging (ASI) and Biocare Medical signed a partnership agreement in which Biocare will distribute ASI’s IHC and CISH imaging and analysis solution, GenASIs Pathology, in the United States. The agreement brings to cytopathology and anatomic pathology laboratories a fully integrated solution that improves quality while providing workflow efficiencies.

Read More »

Supernova antibodies, 8/13:86

Biocare Medical’s Supernova antibodies contain a higher antibody concentration than standard predilutes. Clients now have the option of preserving limited tissue specimens while still providing multi-antigen identification in about the same time as an antibody cocktail. This is achieved using Supernova antibodies in sequential incubations combined with Biocare’s double stain detection. Unique cocktails can also be created with ease as ...

Read More »

Uroplakin II antibody IVD, 7/13:104

Biocare Medical’s uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma. Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor ...

Read More »